Table 4 Anti-HFG mAb immunostaining of human cancerous tissues
From: Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
Organ | Pathology diagnosis | Type | Positive rate | ||
|---|---|---|---|---|---|
Stomach | Adenocarcinoma | Malignant | 57/175 | 32.6% | 33.2% |
| Â | Mucinous adenocarcinoma | Â | 6/17 | 35.3% | Â |
| Â | Undifferentiated adenocarcinoma | Â | 1/2 | 50.0% | Â |
| Â | Signet-ring cell carcinoma | Â | 1/2 | 50.0% | Â |
Colon | Adenocarcinoma | Malignant | 11/23 | 47.8% | 44.0% |
| Â | Mucinous adenocarcinoma | Â | 0/2 | 0.0% | Â |
Breast | Invasive ductal carcinoma | Malignant | 1/23 | 4.3% | 4.2% |
| Â | Mixed lobular and duct carcinoma | Â | 0/1 | 0.0% | Â |
Liver | Hepatocellular carcinoma | Malignant | 1/40 | 2.5% | 2.5% |
Lung | Adenocarcinoma | Malignant | 3/15 | 20% | 20% |
| Â | Squamous cell carcinoma | Â | 2/10 | 20% | Â |
Lymph node | Metastatic adenocarcinoma | Metastasis | 13/40 | 32.5% | 32.5% |
Ovary | Serous adenocarcinoma | Malignant | 0/33 | 0.0% | 5.0% |
| Â | Mucinous adenocarcinoma | Â | 2/6 | 33.3% | Â |
| Â | Endometrial adenocarcinoma | Â | 0/1 | 0.0% | Â |
Pancreas | Duct adenocarcinoma | Malignant | 11/24 | 45.8% | 48.0% |
| Â | Papillary adenocarcinoma | Â | 1/1 | 100.0% | Â |
Prostate | Adenocarcinoma | Malignant | 1/25 | 4.0% | 4.0% |
Uterus | Endometrial adenocarcinoma | Malignant | 10/40 | 25.0% | 25.0% |
Others | Squamous cell carcinoma | Malignant | 1/32 | 3.1% | 3.1% |